ArticleCancer discovery2018
Landscape of Acquired Resistance to Osimertinib in
Abstract read
In one paragraph
Article in Cancer discovery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 270 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
270citing papers in PubMed, 2 pooled it
39.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
270 citing papers in PubMed, 2 syntheses or guidelines pooled it, 441 citations in OpenAlex.
- Resistance Mutation Profiles Associated with Current Treatments for Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer in the United States: A Systematic Literature Review.Current oncology (Toronto, Ont.) · 2025Pooled it
- The impact of EGFR T790M mutation status following the development of Osimertinib resistance on the efficacy of Osimertinib in non-small cell lung cancer: A meta-analysis.The clinical respiratory journal · 2024Pooled it
- Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD).Clinical lung cancer · 2021Trial
- Identification of optimal dosing schedules of dacomitinib and osimertinib for a phase I/II trial in advanced EGFR-mutant non-small cell lung cancer.Nature communications · 2021Trial
- Co-mutation patterns and survival associations in lung cancer: a comparative analysis of Swedish and global cohorts.Acta oncologica (Stockholm, Sweden) · 2026Article
- Discovery of Potent EGFR Inhibitors for Del19 and L858R/T790M Mutants Through Structure-Based Virtual Screening and Biological Evaluation.Chemical biology & drug design · 2026Article
- Sequential EGFR T790M, MET c.3010C>G-Associated Exon 14 Alteration, and RET-CCDC6 Fusion in EGFR-Mutant NSCLC: A Case Report.Thoracic cancer · 2026Article
- Improving dermatological adverse events from amivantamab plus lazertinib: lessons from the COCOON trial.Journal of thoracic disease · 2026Article
- Complete response in disseminatedTranslational lung cancer research · 2026Article
- The global clinical trial landscape of lung cancer cellular therapy current status trends and scientific challenges.Discover oncology · 2026Article
- OB-001 Enhances Osimertinib Brain Penetration: Preclinical Pharmacokinetics and Translational Rationale for EGFR-Mutant NSCLC with CNS Disease.Cancer research communications · 2026Article
- From Passive Sampling to Precision Intervention: A Standardized Radiomics-Driven Workflow for Molecularly Adequate Lung Biopsy.Cardiovascular and interventional radiology · 2026Observational
- The resistance landscape of EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer: molecular mechanisms and novel therapeutic strategies.Translational lung cancer research · 2026Review
- Therapeutic Advances in Non-Small Cell Lung Cancer HarboringInternational journal of molecular sciences · 2026Review
- Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026).Chinese medical journal · 2026Review
- Tolerance and Resistance to Targeted Therapy in NSCLC: Emerging Concepts and Strategies.JTO clinical and research reports · 2026Review
- The oncogenic CCDC6-RET fusion protein is a dual ATP- and ADP-dependent kinase.Nature communications · 2026Article
- Factors influencing diagnostic yield and complication risk in computed tomography fluoroscopy-guided lung biopsies: a 10-year single-center study.Diagnostic and interventional radiology (Ankara, Turkey) · 2026Article
- A Darwinian Perspective on Tumor Evolution.International journal of biological sciences · 2026Review
- Non-small cell lung cancer after EGFR-TKI resistance: from drug resistance mechanisms to precision interventions.Frontiers in pharmacology · 2026Review
210 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 4 institutions in 1 country.
Zofia Piotrowska *Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
Hideko Isozaki *Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
Jochen K LennerzDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
Justin F GainorMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Inga T LennesMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Viola W ZhuChao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California.
Nicolas MarcouxMassachusetts General Hospital Cancer Center, Boston, Massachusetts.ORCID 0000-0003-1422-6716
Mandeep K BanwaitMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Subba R DigumarthyDepartment of Radiology, Massachusetts General Hospital, Boston, Massachusetts.
Wenjia SuMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Satoshi YodaMassachusetts General Hospital Cancer Center, Boston, Massachusetts.ORCID 0000-0003-4201-1392
Amanda K RileyMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Varuna NangiaMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Jessica J LinMassachusetts General Hospital Cancer Center, Boston, Massachusetts.ORCID 0000-0001-7373-3916
Rebecca J NagyGuardant Health, Redwood City, California.
Richard B LanmanGuardant Health, Redwood City, California.ORCID 0000-0001-8122-4329
Dora Dias-SantagataDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
Mari Mino-KenudsonDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
A John IafrateDepartment of Pathology, Massachusetts General Hospital, Boston, Massachusetts.
Rebecca S HeistMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Alice T ShawMassachusetts General Hospital Cancer Center, Boston, Massachusetts.
Erica K EvansBlueprint Medicines, Cambridge, Massachusetts.
Corinne CliffordBlueprint Medicines, Cambridge, Massachusetts.
Sai-Hong I OuChao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, Orange, California.
Beni WolfBlueprint Medicines, Cambridge, Massachusetts.
Aaron N HataMassachusetts General Hospital Cancer Center, Boston, Massachusetts. Lvsequist@partners.org Ahata@mgh.harvard.edu.
Lecia V SequistMassachusetts General Hospital Cancer Center, Boston, Massachusetts. Lvsequist@partners.org Ahata@mgh.harvard.edu.ORCID 0000-0002-8965-6991
Massachusetts General Hospital · USBlueprint Medicines (United States) · USGuardant (United States) · USUniversity of California, Irvine Medical Center · US
Funding
Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical OncologyK12CA087723 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Tsai Ting · 2002 to 2026
$17.9MThe Activation of ERBB3 Signaling as a Resistance Mechanism to Targeted TherapiesR01CA137008 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI Aaron N Hata, ZOFIA PIOTROWSKA · 2009 to 2026
$5.7MEvolution of resistance of EGFR mutant non-small cell lung cancerK08CA197389 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HATA, AARON N · 2016 to 2020
$896kNCI NIH HHS K08 CA197389NCI NIH HHS K12 CA087723NCI NIH HHS R01 CA137008
Abstract
We present a cohort of 41 patients with osimertinib resistance biopsies, including 2 with an acquired
Indexed as
AcrylamidesAdultAgedAged, 80 and overAniline CompoundsCarcinoma, Non-Small-Cell LungCell Line, TumorCohort StudiesCytoskeletal ProteinsDrug Resistance, NeoplasmErbB ReceptorsFemaleHumansIndolesLung NeoplasmsMaleAcrylamidesAniline CompoundsCCDC6 protein, humanCytoskeletal ProteinsEGFR protein, humanErbB ReceptorsIndolesOncogene Proteins, FusionosimertinibProtein Kinase InhibitorsProto-Oncogene Proteins c-retPyrimidinesRET protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.